We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+6.46%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$92.1M
AUM Growth
+$9.88M
Cap. Flow
+$5.78M
Cap. Flow %
6.28%
Top 10 Hldgs %
95.14%
Holding
26
New
6
Increased
10
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
SCYX icon
SCYNEXIS
SCYX
+$8.4M
2
ICMB icon
Investcorp Credit Management BDC
ICMB
+$6.09M
3
UHAL icon
U-Haul Holding Co
UHAL
+$960K
4
PCG icon
PG&E
PCG
+$955K
5
GARS
Garrison Capital Inc.
GARS
+$936K

Top Sells

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$10.1M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$1.04M
3
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$214K
4
ADNT icon
Adient
ADNT
+$60K
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$51.7K

Sector Composition

Rank Sector Weight
1 Healthcare 69.65%
2 Financials 10.36%
3 Real Estate 1.51%
4 Utilities 1.07%
5 Industrials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$47.3M 51.34%
5,376,039
-138,955
-3% -$1.04M
GARS
2
DELISTED
Garrison Capital Inc.
GARS
$9.05M 9.83%
1,115,072
+115,072
+12% +$936K
MTEM
3
DELISTED
Molecular Templates, Inc.
MTEM
$8.31M 9.02%
69,252
+1,666
+2% +$251K
ICMB icon
4
Investcorp Credit Management BDC
ICMB
$12.4M
$6.64M 7.21%
815,440
+744,545
+1,050% +$6.09M
SCYX icon
5
SCYNEXIS
SCYX
$44.5M
$6.53M 7.08%
+60,880
New +$8.4M
AGRX
6
DELISTED
Agile Therapeutics
AGRX
$4.66M 5.06%
907
-3
-0.3% -$19.8K
BRK.B icon
7
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.86M 2.02%
9,312
+367
+4% +$75.4K
JBGS
8
JBG SMITH
JBGS
$877M
$1.39M 1.51%
41,170
– –
PCG icon
9
PG&E
PCG
$38.6B
$988K 1.07%
+22,500
New +$955K
UHAL icon
10
U-Haul Holding Co
UHAL
$14.1B
$932K 1.01%
+27,000
New +$960K
ONCT
11
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$877K 0.95%
353
-96
-21% -$214K
BBDC icon
12
Barings BDC
BBDC
$908M
$543K 0.59%
48,831
+8,251
+20% +$89.6K
FSK icon
13
FS KKR Capital
FSK
$3.11B
$508K 0.55%
17,529
+9,852
+128% +$293K
BUD icon
14
AB InBev
BUD
$157B
$486K 0.53%
+4,425
New +$491K
ABDC
15
DELISTED
Alcentra Capital Corp
ABDC
$446K 0.48%
64,136
+4,574
+8% +$35.3K
INDP icon
16
Indaptus Therapeutics
INDP
$337M
$395K 0.43%
29
-3
-9% -$42.5K
ACRS icon
17
Aclaris Therapeutics
ACRS
$749M
$370K 0.4%
21,142
+3,148
+17% +$66.7K
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.6B
$233K 0.25%
1,999
-419
-17% -$51.7K
ADNT icon
19
Adient
ADNT
$1.62B
$229K 0.25%
3,838
-899
-19% -$60K
DRNA
20
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$125K 0.14%
+13,074
New +$141K
MRNS
21
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$102K 0.11%
6,707
+2,046
+44% +$48.7K
CPRX
22
DELISTED
Catalyst Pharmaceutical
CPRX
$86K 0.09%
36,079
+2,969
+9% +$9.87K
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$78K 0.08%
+940
New +$107K
IWM icon
24
CALL
iShares Russell 2000 ETF
IWM
$82.2B
– –
-6,540
Closed -$997K
KALA icon
25
KALA BIO
KALA
$15.7M
– –
-218
Closed -$10.1M
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2018 Portfolio in Review

As of Q1 2018, Caxton Corporation held 26 positions worth $92.1M, up 12% from $82.3M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Caxton Corporation deployed $5.78M of net new capital in Q1 2018, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was SCYNEXIS: 60,880 shares worth $6.53M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 76% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was Strongbridge Biopharma plc., an estimated $1.04M trimmed.

  • Caxton Corporation's largest Q1 2018 buy was SCYNEXIS: 60,880 shares worth $6.53M.
  • Caxton Corporation added most to Investcorp Credit Management BDC in Q1 2018, an estimated $6.09M increase.
  • Caxton Corporation's biggest Q1 2018 reduction was Strongbridge Biopharma plc., cutting an estimated $1.04M.
  • Caxton Corporation fully exited KALA BIO in Q1 2018, selling an estimated $10.1M.
  • Caxton Corporation's ten largest holdings make up 95% of its $92.1M portfolio in Q1 2018.
  • Caxton Corporation opened 6 new positions and closed 3 in Q1 2018.
  • Caxton Corporation's portfolio value rose 12% quarter-over-quarter to $92.1M.

Based on Caxton Corporation's 13F filing for Q1 2018, filed 15 May 2018.